Physician profile
David Nabert
NPI 1174590863
$7,172.85
in general payments reported to CMS, 2019-2025
33 companies · $792 in 2025
The $792 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,881 · 2020: $724 · 2021: $922 · 2022: $1,142 · 2023: $981 · 2024: $729 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,502.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,431.51 | 2019-2025 | Aveir, Gallant, Assurity |
| Boston Scientific Corporation | $961.52 | 2019-2024 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $398.95 | 2019-2025 | Lifevest |
| Vital Connect, INC | $383.25 | 2023-2025 | Vitalpatch Rtm |
| Novartis Pharmaceuticals Corporation | $369.86 | 2019-2025 | |
| Atricure, INC. | $353.77 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $345.79 | 2019-2025 | Eliquis |
| Amgen INC. | $264.53 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $221.83 | 2019-2022 | |
| Edwards Lifesciences Corporation | $217.37 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Janssen Pharmaceuticals, INC | $167.45 | 2019-2022 | |
| Cvrx, INC. | $135.65 | 2023-2025 | Barostim Neo System |
| Pfizer INC. | $130.13 | 2019-2024 | |
| Amarin Pharma, INC. | $114.98 | 2019-2022 | |
| Philips North America LLC | $91.65 | 2020-2025 | Ambulatory Monitoring & Diagnostics Undivided |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.23 | 2019-2023 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $76.21 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $56.43 | 2019 | |
| Novo Nordisk INC | $54.33 | 2025 | Wegovy |
| Astellas Pharma US INC | $36.12 | 2019-2021 | |
| Abiomed | $34.07 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $30.94 | 2019 | |
| Stryker Corporation | $29.12 | 2025 | Flowtriever |
| Bardy Diagnostics, INC. | $25.02 | 2020-2022 | |
| Lexicon Pharmaceuticals, INC. | $21.36 | 2023 | Inpefa |
| Inari Medical, INC. | $19.56 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| United Therapeutics Corporation | $18.57 | 2019 | |
| Medicomp INC | $17.61 | 2019 | |
| Daiichi Sankyo INC. | $17.13 | 2023 | Injectafer |
| Avinger INC. | $17.10 | 2019 | |
| Merck Sharp & Dohme LLC | $16.06 | 2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $13.94 | 2024 | Arcalyst |
| Baxter Healthcare | $13.81 | 2025 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Nabert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.